Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Journal
The Lancet
Journal Volume
391
Journal Issue
10118
Pages
319-328
Date Issued
2018
Author(s)
Ridker P.M.
MacFadyen J.G.
Everett B.M.
Libby P.
Thuren T.
Glynn R.J.
Kastelein J.
Koenig W.
Genest J.
Lorenzatti A.
Varigos J.
Siostrzonek P.
Sinnaeve P.
Fonseca F.
Nicolau J.
Gotcheva N.
Yong H.
Urina-Triana M.
Milicic D.
Cifkova R.
Vettus R.
Anker S.D.
Manolis A.J.
Wyss F.
Forster T.
Sigurdsson A.
Pais P.
Fucili A.
Ogawa H.
Shimokawa H.
Veze I.
Petrauskiene B.
Salvador L.
Cornel J.H.
Klemsdal T.O.
Medina F.
Budaj A.
Vida-Simiti L.
Kobalava Z.
Otasevic P.
Pella D.
Lainscak M.
Seung K.-B.
Commerford P.
Dellborg M.
Donath M.
Kultursay H.
Flather M.
Ballantyne C.
Bilazarian S.
Chang W.
East C.
Forgosh L.
Harris B.
Ligueros M.
CANTOS Trial Group
Publisher
Lancet Publishing Group
Type
journal article